Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Thermo Fisher Scientific Inc(TMO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TMO
11/06/2026: TMO (3-star) is a STRONG-BUY. BUY for 93 days. Simulated Profits (37.30%). Updated daily EoD!
Thermo Fisher Scientific is a prominent provider of analytical instruments, laboratory supplies, and outsourced pharmaceutical services, acting as a critical partner for the global life sciences and healthcare sectors. The company is known for its extensive distribution network and diversified portfolio, which provide a stable and defensible market position. Its primary growth story revolves around supporting the pharmaceutical industry through its expanded CDMO capabilities. However, investors should monitor risks such as high dependence on R&D spending and the challenges inherent in integrating large acquisitions. The stock may suit growth-oriented investors looking for exposure to healthcare innovation, though its premium valuation and low dividend yield should be factored into investment decisions.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Thermo Fisher has a history of consistent revenue and earnings growth fueled by R&D and strategic M&A. |
| Momentum investor | Mixed fit | Momentum appeal depends on positive price trends and broader sector sentiment toward life sciences. |
| Value investor | Mixed fit | The stock often trades at a premium multiple due to its perceived quality and stable market position. |
| Dividend investor | Mixed fit | It offers a reliable dividend, though the yield is generally low, prioritizing growth over income. |
| Low-risk investor | Strong fit while signal remains positive | The company's diversified nature and essential product portfolio offer relative stability within the healthcare sector. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | As a large-cap stock, it is subject to broader market swings and sector-specific sentiment. |
| Valuation risk | Medium / high | Investors often pay a premium for TMO, which can leave the stock vulnerable if growth targets are missed. |
| Competition risk (Danaher/Agilent) | Medium | The company faces persistent competition in high-margin instrument and lab service segments. |
| Business quality | Strong | The company possesses a deep, defensible moat through its global scale and cross-selling ecosystem. |
| Dividend income | Low | The dividend is stable but not the primary driver of total return for this stock. |
| Execution risk | Medium | Continued success relies on the effective integration of future acquisitions and operational scaling. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 50.56% | Avg. Invested days 52 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 257.42B USD | Price to earnings Ratio 36.64 | 1Y Target Price 752.12 |
Price to earnings Ratio 36.64 | 1Y Target Price 752.12 | ||
Volume (30-day avg) 2.3M shares | Beta 0.84 | 52 Weeks Range 434.50 - 712.17 | Updated Date 11/08/2026 |
52 Weeks Range 434.50 - 712.17 | Updated Date 11/08/2026 | ||
Dividends yield (FY) 0.27% | Basic EPS (TTM) 18.96 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Analytical Technologies | Mass spectrometers, electron microscopes, and chromatography systems. | The company sells the high-tech 'picks and shovels' for scientific discovery. |
| Life Sciences Solutions | Genomics and molecular biology reagents/kits. | Steady revenue generated from essential consumables used in lab experiments. |
| Geography | Revenue generated globally across North America, Europe, and Asia-Pacific. | Global diversification helps insulate the company from regional economic slowdowns. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-21 | When Before Market | Estimate 6.4 | Actual 6.68 |
Profitability
Profit Margin 14.94% | Operating Margin (TTM) 20.19% |
Management Effectiveness
Return on Assets (TTM) 5.19% | Return on Equity (TTM) 13.38% |
Valuation
Trailing PE 36.64 | Forward PE 24.94 | Enterprise Value 292.73B | Price to Sales(TTM) 5.44 |
Enterprise Value 292.73B | Price to Sales(TTM) 5.44 | ||
Enterprise Value to Revenue 6.18 | Enterprise Value to EBITDA 23.34 | Shares Outstanding 370.52M | Shares Floating 369.60M |
Shares Outstanding 370.52M | Shares Floating 369.60M | ||
Percent Insiders 0.13 | Percent Institutions 93.08 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.